GSK’s better-than-expected results overshadowed by Zantac litigation
The British pharmaceutical giant beat expectations but saw its share price drop on investors’ concerns about lawsuits surrounding its Zantac heartburn medicine
The British pharmaceutical giant beat expectations but saw its share price drop on investors’ concerns about lawsuits surrounding its Zantac heartburn medicine
